Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial-Reference-Cited by-同舟云学术

Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial

Published:2018-03 Issue:3 Volume:19 Page:144-154
ISSN:1751-2972
Container-title:Journal of Digestive Diseases
language:en
Short-container-title:Journal of Digestive Diseases

Author:

Wang Yong Feng¹,Tang Jie Ting¹^ORCID,Han Tao²,Ding Hui Guo³,Ye Wei Jiang⁴,Wang Mao Rong⁵,Cheng Jun⁶,Yang Yong Ping⁷,Chen Cheng Wei⁸,Xie Qing⁹,Mao Qing¹⁰,Niu Jun Qi¹¹,Wang Zheng Hua¹,Wei Zhong¹,Chen Ying Xuan¹,Zeng Min De¹,Mao Yi Min¹

Affiliation:

1. Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine; Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease; Shanghai China

2. Division of Hepatology, Tianjin Third Hospital; Tianjin China

3. Division of Gastroenterology and Hepatology, Beijing You’an Hospital, Capital Medical University; Beijing China

4. Department of Infectious Diseases, Xixi Hospital of Hangzhou; Hangzhou Zhejiang Province China

5. Department of Infectious Diseases, Nanjing Bayi Hospital; Nanjing Jiangsu Province China

6. Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University; Beijing China

7. Department of Infectious Diseases, 302 Military Hospital of China; Beijing China

8. Division of Hepatology, 85 Hospital of People’s Liberation Army; Shanghai China

9. Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai China

10. Department of Infectious Diseases, Southwest Hospital; Chongqing China

11. Department of Infectious Diseases, First Hospital of Jilin University; Changchun Jilin Province China

Funder

Zhejiang Otsuka Pharmaceutical. Co., Ltd

Otsuka Beijing Research Institute

Publisher

Wiley

Subject

Gastroenterology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1751-2980.12583/fullpdf

Reference28 articles.

1. High relative fat-free mass is important for maintaining serum albumin levels in patients with compensated liver cirrhosis;Kotoh;World J Gastroenterol,2005

2. Management of cirrhosis and ascites;Ginès;N Engl J Med,2004

3. Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis;Chen;J Clin Gastroenterol,2014

4. Using transjugular intrahepatic portosystemic shunts for complications of cirrhosis;Bhogal;Clin Gastroenterol Hepatol,2011

5. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis;European Association for the Study of the Liver;J Hepatol,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, pharmacodynamics and safety of 15 mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis;Frontiers in Pharmacology;2024-01-26

2. Efficacy and safety of tolvaptan in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials;Expert Review of Gastroenterology & Hepatology;2023-10-03

3. Curative Effect and Safety of Tolvaptan Combined With Traditional Diuretics in Treatment of Patients With Cirrhotic Ascites and Relevant Research on Its Dose;American Journal of Therapeutics;2021-01-04

4. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial;BMC Gastroenterology;2020-11-19

5. Impact of Vaptans on Clinical Outcomes in Cirrhosis Patients: A Meta-Analysis of Randomized Controlled Trials;Frontiers in Pharmacology;2019-11-20